FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Inclusion Criteria: * Patients must have a histologic diagnosis of adenocarcinoma of the esophagus, GEJ, or GC based on biopsy material or adequate cytologic exam; tumors of the GC are defined as originating within 5 cm of the GEJ * Patients must be clinically staged according to the 7th edition (2010) of the American Joint Committee on Cancer (AJCC) staging system and must have either clinical T3-4a, or ≥ N1 disease; staging should include upper endoscopy with endoscopic ultrasound and a fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scan (with diagnostic CT abdomen/pelvis preferred) * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Absolute neutrophil count ≥ 1,500/ul * Platelet count ≥100,000/ul * Serum creatinine (Scr) ≤ 1.5mg/dl; if the Scr \> 1.5, patients may still be eligible if the calculated glomerular filtration rate (GFR) (Cockroft-Gault) is ≥ 40ml/minute * Serum total bilirubin ≤ 1.5X the institutional upper limit of normal (ULN) * Alkaline phosphatase ≤ 3X the institutional ULN * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3X the institutional ULN * Patients with Gilbert's syndrome are eligible provided the total bilirubin is ≤ 3 and the remainder of the liver function tests (ALT, AST, alkaline phosphatase \[ALK Phos\]) are within the institutional normal range * Patients must have a forced expiratory volume in one second (FEV-1) and diffusing capacity of the lu…